nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
A Brighton collaboration standardized template with key considerations for a benefit/risk assessment for a viral vector vaccine based on a non-replicating modified vaccinia virus Ankara viral vector
|
Link, Ellen K. |
|
|
43 |
P1 |
p. |
artikel |
2 |
Assessment of the BNT162B2 COVID-19 vaccine immune response in Brazilian indigenous adolescents
|
de Oliveira, Laís Albuquerque |
|
|
43 |
P1 |
p. |
artikel |
3 |
Australian parents' experiences with adolescent age-based vaccinations during the COVID-19 pandemic
|
Steffens, Maryke S. |
|
|
43 |
P1 |
p. |
artikel |
4 |
Breakthroughs and insights: A comprehensive review of yellow fever vaccine breakthrough infection across 8 decades
|
Coulter, Felicity J. |
|
|
43 |
P1 |
p. |
artikel |
5 |
Burden of Lassa fever disease in pregnant women and children and options for prevention
|
Chaudhary, Manu |
|
|
43 |
P1 |
p. |
artikel |
6 |
Concurrent use of the foot-and-mouth disease and other vaccines in livestock
|
Göktuna, Pelin Tuncer |
|
|
43 |
P1 |
p. |
artikel |
7 |
Corrigendum to “Evaluation of commercial quadrivalent foot-and-mouth disease vaccines against east African virus strains reveals limited immunogenicity and duration of protection” [Vaccine 42 (1–12) (2024) 126325]
|
Kerfua, Susan D. |
|
|
43 |
P1 |
p. |
artikel |
8 |
Development of a candidate vaccine against severe fever with thrombocytopenia syndrome virus using Gn/Gc glycoprotein via multiple expression vectors delivered by attenuated Salmonella confers effective protection in hDC-SIGN transduced mice
|
Park, Ji-Young |
|
|
43 |
P1 |
p. |
artikel |
9 |
Editorial Board
|
|
|
|
43 |
P1 |
p. |
artikel |
10 |
Herpes zoster vaccination among Medicare beneficiaries with and without prescription drug coverage
|
Tsai, Yuping |
|
|
43 |
P1 |
p. |
artikel |
11 |
Immunogenicity of a classical swine fever bait vaccine (Flc-LOM- BErns) in hybrid-wild boars
|
Choe, SeEun |
|
|
43 |
P1 |
p. |
artikel |
12 |
Improving the timeliness and equity of preschool childhood vaccinations: Mixed methods evaluation of a quality improvement programme in primary care
|
Marszalek, Milena |
|
|
43 |
P1 |
p. |
artikel |
13 |
Intranasal immunization with CPAF combined with ADU-S100 induces an effector CD4 T cell response and reduces bacterial burden following intravaginal infection with Chlamydia muridarum
|
Poston, Taylor B. |
|
|
43 |
P1 |
p. |
artikel |
14 |
Live-attenuated vaccine failure after liver transplantation: A 20-year cohort study
|
Furuichi, Munehiro |
|
|
43 |
P1 |
p. |
artikel |
15 |
Modification and validation of a vaccine hesitancy scale for adolescent COVID-19 vaccination
|
Regan, Annette K. |
|
|
43 |
P1 |
p. |
artikel |
16 |
Multisystem inflammatory syndrome in children (MIS-C) cases by vaccination status in California
|
Le Marchand, Chloe |
|
|
43 |
P1 |
p. |
artikel |
17 |
Parental decisions regarding the vaccination of children and adolescents against SARS-CoV-2 from 2020 to 2023: A descriptive longitudinal study of parents and children in Montreal, Canada
|
Charland, Katia |
|
|
43 |
P1 |
p. |
artikel |
18 |
Pertussis vaccination coverage in women at two months postpartum and associated factors in France, National Perinatal Survey 2021
|
Dilange, Lisa |
|
|
43 |
P1 |
p. |
artikel |
19 |
Proteomic signatures of vaccine-induced and breakthrough infection-induced host responses to SARS-CoV-2
|
Williams, Erin |
|
|
43 |
P1 |
p. |
artikel |
20 |
Randomized trial showing persistence of hSBA titers elicited by a pentavalent meningococcal MenABCWY vaccine for up to 4 years following a primary series and safety and immunogenicity of a booster dose
|
Peterson, James |
|
|
43 |
P1 |
p. |
artikel |
21 |
Relative effectiveness of homologous NVX-CoV2373 and BNT162b2 COVID-19 vaccinations in South Korea
|
Gwak, Eunseon |
|
|
43 |
P1 |
p. |
artikel |
22 |
Report of a SPEAC webinar 22 september 2023: Sensorineural hearing loss, lassa virus disease and vaccines
|
Reed, Nicholas S. |
|
|
43 |
P1 |
p. |
artikel |
23 |
Safety and immunogenicity of the Ad26/protein preF RSV vaccine in adults aged 18 to 59 years with and without at-risk comorbidities for severe respiratory syncytial virus disease: A phase 3, randomized, controlled, immunobridging trial
|
Jastorff, Archana |
|
|
43 |
P1 |
p. |
artikel |
24 |
Vaccination strategies to protect chickens from fowl adenovirus (FAdV)-induced diseases: A comprehensive review
|
De Luca, Carlotta |
|
|
43 |
P1 |
p. |
artikel |